Скачать или смотреть 2025 ESMO Prostate Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ESMO 2025.

Highlights in this video include:

PSMA Addition:
1L mCSPC
The first randomized phase III trials of radioligand therapy in mCSPC demonstrating that LuPSMA-617 + ARPI + ADT improves rPFS (HR 0.72) relative to Abiraterone + ADT.

CAPItello-281:
mCSPC w/ PTEN loss (IHC 90%)
Randomized phase III in PTEN deficient mCSPC (IHC great than 90%) demonstrating Capivasertib (AKT inhibitor) + Abiraterone + ADT improves rPFS (HR 0.81) vs ADT/ABI.

EMBARK:
High Risk Biochemical Release:
Enzalutamide + ADT improved MFS and OS (HR 0.59) relative to ADT alone in high risk biochemical relapse (conventional imaging).